Carolina

🔍 Claves: - La aortitis es frecuente y aumenta el riesgo de aneurisma. - La imagen avanzada detecta afectación en hasta el 65% de los casos. - Desacoplamiento clínica-imagen: a los 24m solo un 12-31% de los pacientes con remisión clínica alcanza remisión completa en imagen.

-Difficult to treat RA is a heterogeneous concept -Risk fx: younger onset, high disease activity,erosive disease, comorbidities, depression. -Study in a Spanish cohort with D2T 2/2 inefficacy showed Rituximab, JAKis, and IL-6i had longer survival (hence better tx options). -The ongoing question about D2T RA… Do we have the right diagnosis? #EULAR2025 @RheumNow

#EULAR 2025 Rheumatoid Arthritis Recommendations and Management #Rheumatology #MedTwitter

Neutrophils pivotal in #Behcet's syndrome pathogenesis↔️Target for therapy ▶️Infliximab superior to cyclophosphamide for induction ▶️Adalimumab superior to cyclosporin to reduce uveitis relapse via @RMD_clinic #EULAR2025

ANCA-associated vasculitis: Advances in the treatment 🔹Glucocorticoid-sparing strategies validated 🔹Rituximab remains central in induction & maintenance 🔹Avacopan improves renal outcomes & QoL 🔹Novel agents: next-gen anti-CD20, CAR-T, C5a inhibitors doi.org/10.1038/s41584…

De la máxima utilidad práctica #SER2025 #osteoporosis

Buen resumen de las indicaciones aprobadas en EspA, APs y EII de los JAKinibs 💊

Nuevas recomendaciones @eular_org para el uso de inmunosupresores en embarazo 🤰🏻 y lactancia 🍼 Cada vez más información y menos restricciones Acceso abierto 🔑 ard.eular.org/article/S0003-…

Minuciosa revisión de @Frubijuarez sobre iIL5 & vasculitis #simposioEAS25 🔹Mepolizumab: indicación GEPA y SHE: EC MIRRA✅ estudio MARS✅ 🔹 Benralizumab: EC Fase 3✅ (MANDARA) ➡️no inferior a Mepo 🔹 Reslizumab: sin datos suficientes 🔹 Depemokimab: lo que vendrá…

🔵#simposioEAS25 @SEReumatologia mesa Vasculitis ✔️Jakinib en Arteritis cls gigantes con Dr J Loricera ! Estupenda 👏👏👏

Tratamiento off label en Sjögren #simposioEAS25

Casi el 9️⃣0️⃣% de los ANA que se derivan a Reumatología NO tienen una enfermedad reumatológica (y seguramente no habría que haberlos solicitado). Mucho que pensar…

Which RA patients are at increased risk of JAKi adverse events? Does disease activity matter? in the upadacitinib ph3 trials, high disease activity pts had more: serious infections HZ MACE VTE Active RA is a massive contributor to many AEs in JAKi pts #ACR24 ABST1393 @RheumNow

Ab#0458 #ACR24 10 year outcomes of 176 patients with seroneg RA 32 pts (18%) had change in dx - SpA (11), seropos RA (6), OA (5), crystal (3), CTD (3), Ifn-related/paraneopl/RS3PE, sarcoid (1) 40 (23%) had drug-free remission 30 (17%) started b/tsDMARD @RheumNow

Today, we revisit the question: Can RA be prevented? APPIPRA and ARIAA trials show that abatacept, by blocking T-cell co-stimulation, can delay progression from pre-RA to RA. A minority may avoid long-term therapy—further studies are needed! #YearInReview #ACR24

🫁 KL-6 & IL-18 are correlated with declined lung function in systemic sclerosis-associated Interstitial lung disease. ➡️ Potential biomarkers for SSc-ILD. Presented by @cristianasieir 0685 #ACR24 @ACRheum

Can we prevent RA? APIPPRA, ARIAA - ABA for pre-clinical/very early seropos RA - encouraging findings PRARI - RTX - didn’t meet endpt @RheumNow #ACR24 Review Course

ArPsax o EspAax? 🤔 poco nuevo en esa diapositiva #ACR24 @SEReumatologia @CEADE_ @ConArtritis @accionpsoriasis

Ante una #dactilitis hay q pensar en….🤔 #ACR24 @GRESSER_Espa @SEReumatologia @SMurcianaReuma @accionpsoriasis @CEADE_ @ConArtritis

Causes of recurrent aphthous stomatitis @RheumNow #ACR24 Review Course